Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling.

阅读:2
作者:Ouyang Alu, Qin Xin, Su Bo, Mo Shaojuan, Jiang Jiujun, Wang Zixin, Li Yu, Lu Jiayu, Lin Yangzheng, Wang Jie, Fan Ling, Jin Ronghua
The immunosuppressive tumor microenvironment, orchestrated by tumor cells through multifaceted immune evasion mechanisms, presents a significant challenge to the coordinated regulation of immunocytes. To overcome these limitations, we synthesized metformin glycyrrhetinic acid salt (Met-GA), which exhibits a 189-fold increase in anti-tumor potency compared to free metformin. An injectable Met-GA hydrogel (Met-GA-H) was formed through a "heating-cooling" cycling. To enable in situ gelation at the tumor site, Fe(3)O(4) NPs were incorporated into the Met-GA suspension. This combination leverages Fe(3)O(4) NPs-mediated photothermal triggering to achieve in situ gelation while enabling multitiered immune cell reprogramming, resulting in a multifunctional hydrogel designated as Fe(3)O(4) NPs@Met-GA-H. This Fe(3)O(4) NPs@Met-GA-H not only induced immunogenic cell death (ICD), as evidenced by a 4.7-fold increase in extracellular ATP, a 1.5-fold upregulation of calreticulin (CRT) exposure, and a 1.5-fold downregulation of high-mobility group box 1 (HMGB1), but also promoted M1 macrophage polarization (2.3-fold increase compared to control) and downregulated PD-L1 expression (2.8-fold decrease compared to control). It enables synergistic modulation of tumor cells, macrophages, and T lymphocytes within a unified platform. Quantitative biodistribution analysis showed a 13.0-fold higher tumor retention on day 7 post-administration compared to the free drug. The Fe(3)O(4) NPs@Met-GA-H demonstrated robust immunotherapeutic efficacy in vivo through sustained ICD activation, macrophage reprogramming, immune checkpoint reactivation, and enhanced infiltration of cytotoxic T lymphocytes. This work establishes a regulatory-compliant precision immunotherapy paradigm based on the rational design of FDA-approved components, achieving synchronized spatiotemporal control over tumor-immune interactions.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。